Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCL2

CCL2

Basics

Aliases:
This biomarker is also known as:
  • SMC-CF,
  • Monocyte chemotactic protein 1,
  • MCP1,
  • Monocyte chemotactic and activating factor,
  • SCYA2,
  • MCP-1,
  • MGC9434,
  • small-inducible cytokine A2,
  • Monocyte secretory protein JE,
  • HSMCR30,
  • monocyte chemotactic protein 1,
  • HC11,
  • Small-inducible cytokine A2,
  • C-C motif chemokine 2,
  • GDCF-2,
  • small inducible cytokine subfamily A (Cys-Cys), member 2,
  • monocyte chemoattractant protein-1,
  • monocyte chemotactic and activating factor,
  • chemokine (C-C motif) ligand 2,
  • monocyte secretory protein JE,
  • small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je),
  • monocyte chemoattractant protein 1,
  • MCAF,
  • Monocyte chemoattractant protein 1,

View in BioMuta

Description…

CCL2, also known as MCP-1, is a member of the chemokine superfamily. Chemokines are a family of small cytokines. The four chemokine subfamilies are based on the arrangement of N-terminal cysteine residues of the mature peptide. CCL2 is a member of the CC subfamily, characterized by two adjacent cysteine residues. CCL2 is a chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. CCL2 has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. It binds to chemokine receptors CCR2 and CCR4.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CCL2

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

CCL2, also known as MCP-1, was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.

Announcement